Search results
Johnson & Johnson (NYSE:JNJ) Position Boosted by PVG Asset Management Corp
ETF DAILY NEWS· 5 hours agoPVG Asset Management Corp lifted its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 28.8% during the 4th quarter, according to its most recent disclosure ...
Dakota Johnson’s Stance Against 'Madame Web' Has This Fellow Actor Up in Arms
SheKnows via Yahoo News· 16 minutes agoBefore Madame Web was released earlier this year, Dakota Johnson‘s press tour was already creating...
Johnson & Johnson’s nipocalimab shows promise in Sjögren’s disease trial
Clinical Trials Arena via Yahoo Finance· 8 hours ago"Johnson & Johnson’s nipocalimab shows promise in Sjögren’s disease trial" was originally created...
In-Depth Examination Of 11 Analyst Recommendations For Johnson & Johnson - Johnson & Johnson...
Benzinga· 4 hours agoPrice Targets: Analysts navigate through adjustments in price targets, providing estimates for Johnson & Johnson's future value. Comparing ...
Johnson & Johnson agrees to pay $700M to settle talcum lawsuit with dozens of states
UPI· 5 days agoU.S. pharmaceutical giant Johnson & Johnson has agree to pay $700 million to settle lawsuits filed...
Johnson & Johnson (NYSE:JNJ) Shares Bought by Putnam Investments LLC
ETF DAILY NEWS· 5 days agoPutnam Investments LLC’s holdings in Johnson & Johnson were worth $97,959,000 at the end of the most recent reporting period. Keener ...
Investors in Johnson & Johnson (NYSE:JNJ) have unfortunately lost 2.7% over the last three years
Simply Wall St. via Yahoo Finance· 6 days agoFor many investors, the main point of stock picking is to generate higher returns than the overall...
Johnson & Johnson reaches $700 million talc settlement with US states
WHTC 1450 Holland· 6 days agoNEW YORK (Reuters) -Johnson & Johnson has agreed to pay $700 million to settle an investigation by...
J&J’s DePuy Synthes orthopedics robot cleared for partial knee replacements
FierceBiotech· 3 hours agoJohnson & Johnson MedTech’s orthopedics division, DePuy Synthes, has claimed an FDA clearance for...
J&J's phase 2 Sjögren's data support FcRn strategy in the autoimmune disorder
FierceBiotech· 5 hours agoThe unveiling of Johnson & Johnson’s full data from the phase 2 trial of nipocalimab in Sjögren's disease (SjD) suggest ...